Thank you for joining ICG-17, Riga!
7 - 9 SEPTEMBER 2022
Riga, Latvia
ICG-17 news and highlights
ABOUT ICG-17, Riga

Over the last 17 years, the International Conference on Genomics (ICG) has been the meeting point for leaders in the emerging field of Genomics to meet and share their experience, knowledge, insights, and questions, to advance understanding and craft collaborations. An integral component of the International Conference on Genomics, ICG-17, Riga will bring together in Riga Latvia, high level scientists, practitioners and institutional executives from Europe and Africa and an international team of expert speakers under the theme OMICS FOR ALL to explore the leading edge in scientific areas. ICG-17, Riga will be a European branch event alongside the Annual International Conference of Genomics hosted in China, which will take place in the same week. In addition participants will be given an information rich tour of the new MGI facilities in Riga and the opportunity to meet the leaders of BGI/MGI Europe and Africa. The event will be both onsite and streamed for remote viewing.



MGI Tech Co., Ltd.
MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time, panoramic, and full-life-cycle equipment and systems for precision medicine, precision agriculture, precision healthcare and other relevant industries. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.
BGI Genomics
BGI Genomics is the world’s leading provider of genomic sequencing services and proteomic services, now serving customers in more than 100 countries. We provide academic institutions, pharmaceutical companies, health care providers, and other organizations with integrated genomic sequencing and proteomic services and solutions across a broad range of applications spanning:
• Basic research covering human, plant, animal, and microbial species
• Clinical research in human health
• Genetic testing and screening
• Drug discovery and development
• Agriculture and Biodiversity preservation and sustainability
We have more than 20 years of genomics experience helping our customers achieve their research goals by delivering rapid, high-quality results using a broad array of cost-effective, cutting-edge technologies, including our own innovative DNBseq™ sequencing technology.
Latvian Biomedical Research and Study Centre (BMC)
Latvian Biomedical Research and Study Centre (BMC) is the leading scientific institute in molecular biology and biomedicine in Latvia. Since its establishment in 1993 it has evolved into a powerful scientific centre performing basic as well as applied research in three major directions: human genetics and disease mechanisms; cancer research; structural biology, and biotechnology virology. In the frame of Human genetics and disease research direction, BMC performs genetic, epigenetic, and microbiome research and studies the mechanisms associated with disease pathogenesis, detection of various biomarkers and development of molecular diagnostic tests. BMC also hosts the National Biobank, the Genome Database of Latvian Population (VIGDB), which includes more than 38,000 participants from the Latvian population and patients from various disease cohorts. This biobank serves as a key resource for increasing the volume of molecular research at BMC, as well as a base for medical innovation and integrated, functional research.​
BGI Research 
BGI Research is one of the top ten basic research institutes in Shenzhen. After years of dedication in genomics research, BGI Research has become a world-leading research center. Focusing on developing gene reading, writing and storage technologies, and leading international big data and disease prevention mega-science programs, BGI Research aims to establish a comprehensive scientific research system covering bioinformatics, human genomics, agricultural genomics, microbiology, and marine biology. 
Riga, Latvia​

Established in 1201, Riga is the capital city of Latvia and the largest and liveliest of the Baltic capitals. The city has developed as a center for trade, transit and industrial center, and has been famed for its beautiful Art Nouveau architecture. In the historical and geographical center of the Latvian capital, the Old Town in Riga is a popular entertainment district featuring cobble-stone streets, Medieval-era buildings and an abundance of architectural gems becoming a worldwide cultural landmark. Boasting of one of the highest concentration's of Art Nouveau structures in the world, rich history, buildings built in various architectural styles, modern art centers and experimental restaurants there are many reasons why Riga is a place that is well worth visiting.

The ICG-17, Riga event will be hosted at the Park Inn by Radisson Riga Valdemara conference venue in Riga Old Town. The venue spans 305 square meters and offers additional breakaway meeting rooms, onsite hotel accommodation and restaurant for added comfort and flexibility during the conference. Located on the west bank of the Daugava River, close to the city center and many top attractions, the venue is only a 12-minute drive from Riga International Airport (RIX) and is 2 public transport stops from the UNESCO Heritage-listed Old Town, providing an opportunity to discover Riga's cultural attractions from a convenient city center base. The venue provides comfort in one of their 178 rooms to admire panoramic views of the Daugava River, Old Town, and city parks and on-site Bocca Buona restaurant which is ideal to indulge in flavorful, freshly-made specialties.

The Park Inn by Radisson Riga Valdemara
MGI Latvia

The nerve center of MGI’s dedicated Europe & Africa R&D and customers service operations, MGI Latvia was inaugurated in November 2019, and today with a staff of over 60 scientific, technical and support professionals, acts as a dynamic hub for research and development, production, logistics and training to support MGI’s customers and scientific collaborator in Europe and Africa. MGI Latvia Sequencing Centre is an 8,000 sq meter technical facility and lab housing a comprehensive training and customer support center that ensure rapid response to the needs of Europe and Africa. In 2021, MGI Latvia was awarded the coveted ISO 13485 Standard and will soon inaugurate a sequencing kit manufacturing plant.


· Global success stories and major projects and collaborations: how can research add value to the community;
· Riga facility onsite visit.

ICG-17: OMICS for all

Understanding the complexity of genes functions requires spatially resolved gene expression profiling with single-cell resolution. Single-cell and Stereomics are new eras for genome research, that represent a major advance toward the systematic understanding of tissue complexity. In this session, we will discuss with leading scientists the advantages of stereomics and single-cell research and talk about their results and progress in single-cell analysis and stereomics. The agenda will include items about single-cell full-length RNA research using Oxford Nanopore devises and C4, Smart-seq automation and others.

Spatially resolved gene expression profiling with single-cell resolution
Leveraging multi-omics approaches and the promise of microbiome

With the development and evolution in NGS studies for all the different omics fields, like genomics, metagenomics, transcriptomics and others, it is being recognized that understanding of mutually influencing processes might be possible with the integrated multi-omics approach. In this session we may discuss the novel metagenome associative research, multiomics insights into biological events, the need for a multi-ecosystem approach to microbiome studies, links between different omics areas and the mechanisms of action for different diseases.

Globally multidisciplinary consortiums have been working proactively with local governments and leaders in the research community to mobilize a coordinated response to the global emergency caused by novel coronavirus COVID-19. Genomics in particular has allowed researchers to identify new variants, provide an understanding on how the virus spreads, unravel how the immune system responds, understanding of why some people appear minimally affected while others are severely impacted, and which pharmaceutical strategies might optimally help reduce the spread and alleviate symptoms for example. This has caused a global emergence in genomics approach to disease outbreaks and understanding of disease progression, including long COVID. In the session we may discuss the importance of the global emergence of genomics to fight outbreaks, discussing the real-time assessment of community transmission, focus on understanding long covid from scientific sessions and Covid-19 host genetic initiatives.

Multidisciplinary view on COVID-19 research

Biobanks provide an indispensable infrastructure for modern research with systematic collections of human biological materials, associated clinical and lifestyle data, and an accumulation of vast amounts of research findings, including participants’ genomic data. From a research perspective the interest in biobanking continues to intensify however many profound legal and ethical challenges remain unresolved. In this session we may discuss the role of biobanks and health data management in personalized medicine development through data safe havens, firsthand response from large Biobanks, and overall ethics surrounding science.

Role of biobanks and health data in personalised medicine development

Precision / Genomic medicine has helped to guide healthcare providers to diagnose rare genetic disorders, to monitor the threat of drug resistance, provide genetic contributions to a patient's health and susceptibility or resilience to disease, or their response to therapeutic interventions. As a result genome sequencing and research into the genomic changes associated with certain disease, including defining cancer types and subtypes for example, has shown a role to play in the future of healthcare and medicine by providing patients with a more precise diagnosis, and therefore a more personalized treatment strategy. In this session we may discuss personalized medicine developments, the international consortium for personalized medicine and project that aims to identify areas of mutual interest for the collaboration in health and PM research, the importance of genomics in oncology and others.

Precision medicine: the future of healthcare

Wednesday 7 September 2022
Workshop Agenda Day 1: Hosted by BGI Group
Thursday 8 September 2022
Workshop Agenda Day 2: Hosted by BGI Group
Friday 9 September 2022
Workshop Agenda Day 3: Hosted by BMC
Woman in science

Session of women scientists brings together top women scientists in the field of life science and big data research, covering a wide range of fields of life science, including evolution, omics, cancer, complex diseases, reproductive health, technology development and bioinformatics.

© MGI Tech Co., Ltd., All rights reserved
Contact Us

Thank you for joining ICG-17, Riga!

MGI Tech Co. Ltd. (MGI), in collaboration with BGI Genomics, BGI Research and the Latvian Biomedical Research and Study Centre, has brought the 17th International Conference of Genomics (ICG-17) to Europe this year on 7-9 September in Riga, Latvia. At ICG-17, MGI introduces its new commercial sequencing chemistry HotMPS* and together with BGI STOmics, a spatial transcriptomics grant program.

Under the theme OMICS FOR ALL, ICG-17 aims to provide a platform where leaders in the emerging field of genomics meet and share their experience, knowledge, and insights, to advance understanding and collaborations in omics. This year’s conference is held in Riga, a trade, transit, and industrial center in Latvia, as well as home to MGI’s Latvian facility, which since 2019 has been a dynamic hub for research and development, production, logistics and training for its customers and scientific collaborators in Europe and Africa.

ICG-17 promises to provide a comprehensive and insightful scientific agenda filled with presentations and sharing by expert speakers and scientific sessions on topics including single-cell and Stereomics, microbiome and multi-omics, precision medicine, multidisciplinary view on COVID-19 research, women in science, and biobanks and health data in personalized medicine development. The event also sees MGI scientists sharing the data performance of the new HotMPS* chemistry on DNBSEQ-G400** and DNBSEQ-T7**, including results on various applications such as WGS, WES, RNA-seq, and third-party libraries.

HotMPS* inherits the advantages of MGI’s proprietary DNBSEQTM technology*** to deliver low error rates, low duplication rates, and low index hopping, while achieving fundamental breakthroughs in the nucleotides and enzymes used in the sequencing process. The high-throughput sequencing kit*, which is commercially available in selected countries, was launched to be compatible with DNBSEQ-G400** in late April and has now been further expanded for use on DNBSEQ-T7** which vastly improves speed, throughput, and flexibility. In his presentation, key speaker Dr. István Szatmári from the University of Debrecen in Hungary showcases the quality of the new chemistry on MGI platform and confirms the suitability of HotMPS* combined with DNBSEQ-G400** for global transcript profiling.

At the ICG-17 in Riga, BGI STOmics announces a spatial transcriptomics grant program, which will provide 12 Stereo-seq (Spatial Enhanced Resolution Omics-Sequencing) chips (1cm*1cm), sequencing and data analysis to selected projects by researchers across the globe, excluding mainland China. MGI will provide MGI sequencing products for this Grant. This new groundbreaking spatial temporal technology provides a powerful research base for advanced analysis of gene expression, cell type identification and cell-to-cell communication in nascent tissue microenvironment with its unprecedented field-of-view, high throughput, ultra-high resolution in spatial transcriptomic research. Based on DNA Nanoball (DNB) technology, Stereo-seq chip is designed for in situ mRNA capture and localization. Subsequently captured mRNAs can be restored to their spatial positions by establishing the mapping relationship between spatial coordinates ID (CID) and chip's coordinate positions, while spatially resolved molecular information can also be obtained using Stereo-seq.

“I am thrilled that so many brilliant minds from Europe, Africa and beyond are gathering to share their knowledge and experience in further advancing genomics science,” said Dr. Yong Hou, General Manager of MGI Europe and Africa. “With the mission to develop and promote advanced life science tools for future healthcare, we at MGI are proud to introduce our latest innovations. DNBSEQ-T7* boasts high data quality and flexible operation mode. Its high degree of automation maximizes DNBSEQ-T7’s* powerful data output capacity and effectively saves manpower and material costs. It fully supports genome-wide sequencing, ultra-high-depth whole exome sequencing, epigenome sequencing, tumor large gene detection, and other application scenarios with its high speed, high flexibility, and ultra-high throughput advantages. In addition, we are excited to facilitate scientific discoveries through fruitful discussions at ICG-17, while empowering scientists with our new Stereo-seq grant.”

Since 2006, ICG has brought together over 1,000 top scientists, practitioners, institutional executives, Nobel Laureates, academics, and entrepreneurs from around the world for open sharing and discussion related to OMICS. There have been more than 10,000 on-site attendees and 10 million from online in the past 17 years.

"Bringing brilliant minds together is always a good idea,” said Prof. Fred Dubee of BGI and key founder of ICG. “I am excited to meet everyone during ICG-17.”

ICG-17 is a hybrid conference and online event registration is open for all here. For more information about the event, please also visit the official website here.

About MGI

MGI Tech Co., Ltd. (MGI), an affiliate of BGI Group, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments***, reagents***, and related products to support life science research, agriculture, precision medicine and healthcare. MGI's mission is to develop and promote advanced life science tools for future healthcare. As of December 2021, MGI has a footprint that spans across more than 80 countries and regions, serves over 1,300 international users and employs more than 2,050 professionals globally, around 35% of which are R&D personnel. For more information, please visit MGI website or connect on TwitterLinkedIn or YouTube.


The HotMPS sequencing reagent can only be used with MGI’s sequencer whose software has been configured for HotMPS, and will not work effectively with MGI’s sequencer whose software has not been properly configured for HotMPS. Use of these reagents with sequencers whose software has not been configured for HotMPS will invalidate any warranty which may have been provided by MGI, and any liability for intellectual property infringement arising from the use of such reagents is excluded from any IP indemnity.

MGI’s sequencer whose software has been configured for HotMPS MUST be used in conjunction with MGI’s HotMPS sequencing reagent, and MUST NOT be used with MGI’s CoolMPS or StandardMPS reagents (or with any reagents containing a 3’O-azidomethyl blocking group). This is important because (i) such sequencers will not work effectively with MGI’s CoolMPS or StandardMPS reagents (or with any reagents containing a 3’O-azidomethyl blocking group); and (ii) the use of such reagents will give rise to the risk of patent infringement proceedings. Use of MGI’s CoolMPS or StandardMPS reagents (or with any reagents containing a 3’O-azidomethyl blocking group) with such sequencers will invalidate any warranty which may have been provided by MGI, and any liability for intellectual property infringement arising from the use of such reagents is excluded from any IP indemnity.

*This sequencing reagent is only available in selected countries.
**This sequencer is only available in selected countries, and its software has been specially configured to be used in conjunction with MGI’s HotMPS sequencing reagents exclusively.
***Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, Spain, UK, Hong Kong, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal, Austria and Romania. No purchase orders for StandardMPS products will be accepted in the USA until after January 1, 2023
Made on